Merck & Co., Inc.
MRK
Key stats
- Open
- 148.61
- Day high
- 149.31
- Day low
- 146.86
- Previous close
- 147.18
- Volume
- 6.11M
- VWAP
- 147.67
- 52-week high
- 156.92
- 52-week low
- 90.90
- Market cap
- 362.83B
- Shares out
- 2.47B
- Employees
- 75,000
- Listed
- 1949
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
PHARMACEUTICAL PREPARATIONS · RAHWAY, NJ · merck.com
Options · expiring Nov 13
Nov 12, 4:00 PM ET- Call open interest
- 7.9K
- Put open interest
- 5.0K
- Put/call
- 0.63
- At-the-money IV
- 20.3%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 152.50 call | 0.03 | Nov 12, 3:57 PM | 1.2K | 595 | 31.6% |
| 150 call | 0.11 | Nov 12, 3:56 PM | 807 | 1.4K | 25.2% |
| 149 call | 0.39 | Nov 12, 3:47 PM | 367 | 439 | 23.8% |
| 140 put | 0.05 | Nov 12, 3:57 PM | 244 | 351 | 54.8% |
| 146 put | 0.55 | Nov 12, 3:50 PM | 167 | 401 | 42.3% |
| 139 put | 0.01 | Nov 12, 1:02 PM | 100 | 186 | 72.3% |
Quarterly results
Massive · Nov 4, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $18.09B | $16.61B | $16.29B | $16.40B |
| Gross profit | $13.19B | $12.21B | $12.09B | $10.85B |
| Operating income | $5.59B | −$584.00M | −$3.40B | $3.85B |
| Net income | $5.07B | −$1.33B | −$4.24B | $2.96B |
| Diluted EPS | 2.04 | -0.54 | -1.72 | 1.19 |
| Operating cash flow | $6.56B | $5.37B | $3.92B | $2.86B |
| Assets | $132.77B | $129.80B | $128.69B | $136.87B |
| Liabilities | $87.83B | $87.82B | $82.75B | $84.20B |
| Equity | $44.95B | $41.98B | $45.93B | $52.66B |
Technicals
Massive · Nov 12, 2026- 50-day average146.22
- 200-day average128.45
- RSI (14 days)51.4
Short interest
Massive · Oct 30, 2026- Oct 30, 202626.60M shares · 2.4 days to cover
- Oct 15, 202626.83M shares · 3.0 days to cover
- Sep 30, 202628.27M shares · 2.5 days to cover
- Sep 15, 202634.43M shares · 4.2 days to cover
Dividends
Massive · Sep 15, 2026- Ex Sep 15, 2026, paid Oct 7, 20260.8500 · 4 a year
- Ex Jun 15, 2026, paid Jul 8, 20260.8500 · 4 a year
- Ex Mar 16, 2026, paid Apr 7, 20260.8500 · 4 a year
- Ex Dec 15, 2025, paid Jan 8, 20260.8500 · 4 a year
- Ex Sep 15, 2025, paid Oct 7, 20250.8100 · 4 a year
- Ex Jun 16, 2025, paid Jul 8, 20250.8100 · 4 a year
- Ex Mar 17, 2025, paid Apr 7, 20250.8100 · 4 a year
- Ex Dec 16, 2024, paid Jan 8, 20250.8100 · 4 a year
Related companies
MassiveNews coverage
No stories about Merck & Co., Inc. right now.